- Home
- NBBK vs ABUS Comparison
NBBK vs ABUS Comparison
Compare NBBK & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NBBK | ABUS |
|---|---|---|
| Founded | 1892 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 884.7M |
| IPO Year | 2023 | 2008 |
Fundamental Metrics
Financial Performance| Metric | NBBK | ABUS |
|---|---|---|
| Price | $20.66 | $4.40 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $23.50 | $5.00 |
| AVG Volume (30 Days) | 299.1K | ★ 2.2M |
| Earning Date | 04-23-2026 | 01-01-0001 |
| Dividend Yield | ★ 1.34% | N/A |
| EPS Growth | ★ 25.23 | 13.64 |
| EPS | ★ 1.34 | N/A |
| Revenue | N/A | ★ $6,171,000.00 |
| Revenue This Year | $45.15 | $125.30 |
| Revenue Next Year | $4.18 | N/A |
| P/E Ratio | $15.56 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.09 | $2.71 |
| 52 Week High | $22.70 | $5.10 |
Technical Indicators
Market Signals| Indicator | NBBK | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 41.64 | 48.63 |
| Support Level | $20.26 | $4.23 |
| Resistance Level | $22.65 | $4.76 |
| Average True Range (ATR) | 0.68 | 0.23 |
| MACD | -0.11 | -0.04 |
| Stochastic Oscillator | 18.63 | 31.25 |
Price Performance
Historical ComparisonAbout NBBK NB Bancorp Inc.
NB Bancorp Inc operates as the holding company of Needham Bank. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in commercial real estate and multifamily loans, one- to four-family residential real estate loans, construction and land development loans, commercial and industrial loans, consumer loans, and other related services.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.